CYP17A1 and Increased circulating aldosterone concentration: These drugs work through distinct mechanisms; abiraterone inhibits androgen biosynthesis through CYP17 blockade and requires concomitant corticosteroids to prevent mineralocorticoid excess, while enzalutamide acts as a potent androgen receptor antagonist that also prevents nuclear translocation of the receptor [1].